TXGHealthcare · Health Information ServicesThe 16 Wall Street analysts covering 10X Genomics, Inc. hold a median 12-month price target of $40 — -14.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 1 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores 10X Genomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Issuance (40): The company has been issuing shares or taking on financing, diluting existing holders.
Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own 10X Genomics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on TXG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −14.9% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 July 2026 | Leerink Partners | Maintains | Market Perform | $23 → $40 |
| 14 July 2026 | Canaccord Genuity | Maintains | Buy | $32 → $50 |
| 9 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 9 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $22 → $37 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 8 July 2026 | Citigroup | Maintains | Neutral | $24 → $45 |
| 1 July 2026 | Piper Sandler | Maintains | Neutral | — |
| 24 June 2026 | Barclays | Maintains | Overweight | — |
| 12 May 2026 | JP Morgan | Maintains | Neutral | — |
| 12 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 20 Apr 2026 | B of A Securities | Maintains | Neutral | — |
| 20 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 7 Apr 2026 | Citigroup | Maintains | Neutral | — |
| 31 Mar 2026 | William Blair | Upgrade | Outperform | — |
| 2 Mar 2026 | Stifel | Maintains | Buy | — |
| 20 Feb 2026 | UBS | Maintains | Neutral | — |
| 13 Feb 2026 | Stifel | Maintains | Buy | — |
| 13 Feb 2026 | TD Cowen | Maintains | Hold | — |
| 27 Jan 2026 | Leerink Partners | Maintains | Market Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 15% of US stocks
Cheaper than 14% of US stocks
Cheaper than 97% of US stocks
Higher than 24% of US stocks
Higher than 33% of US stocks
Higher than 83% of US stocks
Higher than 25% of US stocks
Higher than 25% of US stocks
Higher than 41% of US stocks
Higher than 33% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TXG appears on the weeks it earns a place.
Zacks Investment Research reported that 10x Genomics (TXG) has the right combination of key ingredients for a likely earnings beat in its upcoming report.
Why it matters — TXG watchers would care because an earnings beat could influence the stock's near-term performance and signal the company's financial health.
10x Genomics announced a research collaboration with Lausanne University Hospital to explore diagnostic applications of the company's single cell and spatial technologies in cancer care, with a focus on identifying biomarkers that could predict treatment response across multiple cancer types.
Why it matters — The collaboration signals potential expansion of 10x's platforms from research tools toward diagnostic applications in oncology, which could broaden their commercial use case.
The 16 Wall Street analysts covering 10X Genomics, Inc. have a median 12-month price target of $40, with estimates ranging from $25 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering 10X Genomics, Inc., 6 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 10X Genomics, Inc. 95 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, 10X Genomics, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies -14.9% from the last close, and Ticker Nerd's factor model ranks 10X Genomics, Inc. 95 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering 10X Genomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TXG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $50 over the next 12 months.
10X Genomics, Inc. returned +259.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
10x Genomics Inc. is a life science technology company that provides advanced tools for high-resolution analysis of biological systems.
The most recent item we track (Zacks Investment Research, 30 July 2026): "10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?". Zacks Investment Research reported that 10x Genomics (TXG) has the right combination of key ingredients for a likely earnings beat in its upcoming report.
10x Genomics Inc. is a life science technology company that provides advanced tools for high-resolution analysis of biological systems. The company focuses on single-cell and spatial biology, offering integrated solutions that combine instruments, consumables, and software for researchers worldwide. Its core product portfolio includes the Chromium platform for single-cell and multiomic analysis, enabling detailed transcriptomic profiling, immune profiling, and other genomic applications at the level of individual cells. 10x Genomics also offers the Visium spatial platform for spatial gene expression studies and the Xenium in situ platform for high-plex tissue profiling, supporting work in oncology, immunology, neuroscience, and other complex disease areas. These technologies are used by academic institutions, pharmaceutical and biotechnology companies, and government research organizations to interrogate biological complexity and generate high-dimensional molecular data. Founded in 2012 and headquartered in Pleasanton, California, United States, 10x Genomics operates across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific, playing a significant role in modern genomics and biomedical research infrastructure.
CEO Dr. Serge Saxonov Ph.D. · 1,178 employees · United States · https://www.10xgenomics.com